Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Should Patients with Extrapulmonary Small-Cell Carcinoma Receive Prophylactic Cranial Irradiation?

Should Patients with Extrapulmonary Small-Cell Carcinoma Receive Prophylactic Cranial... BRIEF REPORT Should Patients with Extrapulmonary Small-Cell Carcinoma  Receive Prophylactic Cranial Irradiation? Jarushka Naidoo, MB BcH BAO, MRCPI,* Min Yuen Teo, MB BcH BAO,† Sandra Deady, MB BcH BAO,‡ Harry Comber, MB BcH BAO,‡ Paula Calvert, MB Bch BAO, MRCPI* mall-cell carcinomas (SCLCs) are a subset of neuroen- Introduction: Extrapulmonary small-cell carcinoma (EPSCC) is a Sdocrine tumors with poor differentiation, elevated mitotic rare disease. Management is based on small-cell lung carcinoma. rate, and a high proliferation index. These cancers are bio- Prophylactic cranial irradiation (PCI) is not routinely administered logically aggressive, disseminate early, and have a poor over- in EPSCC. This study investigates the role of PCI in EPSCC, by ana- all prognosis. SCLCs most commonly originate in the lung. lyzing the incidence, treatment, and survival of patients with brain Between 10 and 14% of patients with SCLC present with brain metastases in a national cohort. Disease biology and epidemiology metastases at diagnosis, and 80% will develop brain metasta- are also investigated. ses within 2 years of diagnosis. Prophylactic cranial irradia- Methods: Patients diagnosed with primary EPSCC from the tion (PCI) reduces the morbidity and mortality associated with National Cancer Registry of Ireland from 1995 to 2007 were identi- brain metastases in SCLC. Phase III studies demonstrate http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Should Patients with Extrapulmonary Small-Cell Carcinoma Receive Prophylactic Cranial Irradiation?

Journal of Thoracic Oncology , Volume 8 (9) – Sep 1, 2013

Loading next page...
 
/lp/wolters-kluwer-health/should-patients-with-extrapulmonary-small-cell-carcinoma-receive-qFgnYbJhbM

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2013 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0b013e31829f6b03
pmid
23945390
Publisher site
See Article on Publisher Site

Abstract

BRIEF REPORT Should Patients with Extrapulmonary Small-Cell Carcinoma  Receive Prophylactic Cranial Irradiation? Jarushka Naidoo, MB BcH BAO, MRCPI,* Min Yuen Teo, MB BcH BAO,† Sandra Deady, MB BcH BAO,‡ Harry Comber, MB BcH BAO,‡ Paula Calvert, MB Bch BAO, MRCPI* mall-cell carcinomas (SCLCs) are a subset of neuroen- Introduction: Extrapulmonary small-cell carcinoma (EPSCC) is a Sdocrine tumors with poor differentiation, elevated mitotic rare disease. Management is based on small-cell lung carcinoma. rate, and a high proliferation index. These cancers are bio- Prophylactic cranial irradiation (PCI) is not routinely administered logically aggressive, disseminate early, and have a poor over- in EPSCC. This study investigates the role of PCI in EPSCC, by ana- all prognosis. SCLCs most commonly originate in the lung. lyzing the incidence, treatment, and survival of patients with brain Between 10 and 14% of patients with SCLC present with brain metastases in a national cohort. Disease biology and epidemiology metastases at diagnosis, and 80% will develop brain metasta- are also investigated. ses within 2 years of diagnosis. Prophylactic cranial irradia- Methods: Patients diagnosed with primary EPSCC from the tion (PCI) reduces the morbidity and mortality associated with National Cancer Registry of Ireland from 1995 to 2007 were identi- brain metastases in SCLC. Phase III studies demonstrate

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Sep 1, 2013

There are no references for this article.